Bortezomib in the Treatment of Multiple Myeloma

Nonfiction, Health & Well Being, Medical, Specialties, Oncology, Medical Science, Pharmacology
Cover of the book Bortezomib in the Treatment of Multiple Myeloma by , Springer Basel
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9783764389482
Publisher: Springer Basel Publication: October 20, 2010
Imprint: Springer Language: English
Author:
ISBN: 9783764389482
Publisher: Springer Basel
Publication: October 20, 2010
Imprint: Springer
Language: English

Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways. This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways. This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.

More books from Springer Basel

Cover of the book Fish Vaccines by
Cover of the book Antimicrobial Peptides and Innate Immunity by
Cover of the book The Scholar and the State: In Search of Van der Waerden by
Cover of the book Capsaicin as a Therapeutic Molecule by
Cover of the book And Yet It Is Heard by
Cover of the book Problem-Solving Methods in Combinatorics by
Cover of the book IL-17, IL-22 and Their Producing Cells: Role in Inflammation and Autoimmunity by
Cover of the book Kripke’s Worlds by
Cover of the book Developments of Harmonic Maps, Wave Maps and Yang-Mills Fields into Biharmonic Maps, Biwave Maps and Bi-Yang-Mills Fields by
Cover of the book Real Quaternionic Calculus Handbook by
Cover of the book Berichte zu Pflanzenschutzmitteln 2011 by
Cover of the book Around and Beyond the Square of Opposition by
Cover of the book Untranslated Gene Regions and Other Non-coding Elements by
Cover of the book Counting Surfaces by
Cover of the book Recent Developments of Mathematical Fluid Mechanics by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy